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Abstract
Background: Activated protein C (APC) inhibits coagulation by degrading activated factor V (FVa)
and factor VIII (FVIIIa), protein S (PS) functioning as a cofactor to APC.
Methods: By mutagenesis of the vitamin K-dependent Gla domain of APC, we have recently
created an APC variant having enhanced anticoagulant activity due to increased affinity for
negatively charged phospholipid membranes. In the present study, the potential antithrombotic
effects of this APC variant, and of a variant APC that is additionally mutated in the serine protease
domain, have been evaluated in a blind randomized study in a rat model of arterial thrombosis. In
this model, we have previously found the combination of bovine APC and PS to be highly
antithrombotic. Four treatment groups each containing 10 rats were, in a blind random fashion,
given intravenous bolus injections of wild-type or mutant variants of APC (0.8 mg/kg) together with
human PS (0.6 mg/kg) or human PS (0.6 mg/kg) alone. A control group with 20 animals where given
vehicle only.
Results: A trend to increased patency rates was noted in a group receiving one of the APC
variants, but it did not reach statistical significance.
Conclusion: In conclusion, administration of human APC variants having enhanced anticoagulant
efficacy together with human PS in a rat model of arterial thrombosis did not give an efficient
antithrombotic effect. The lack of effect may be due to species-specific differences between the
human protein C system and the rat hemostatic system.
Background
Activated protein C (APC) is an endogenous anticoagu-
lant, which is crucially important for the regulation of
blood coagulation [1-6]. APC is generated by limited pro-
teolysis of its zymogen protein C by thrombin bound to
its cofactor thrombomodulin on the surface of intact
endothelium. APC effectively down-regulates the coagula-
tion processes by selectively degrading the activated coag-
ulation cofactors factor V (FVa) and factor VIII (FVIIIa).
Protein S (PS) is a cofactor to APC in the regulation of FVa
and FVIIIa. The importance of protein S as a cofactor in
the anticoagulant protein C system is illustrated by the
increased risk of venous thrombosis in individuals with a
hereditary deficiency of the protein [7,8]. The molecular
mechanisms involved in the enhancement by PS in the
APC-reactions are incompletely understood. PS has been
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suggested to increase the affinity of APC to phospholipid
membranes [9] but also to alter the orientation of the
active site of APC [10].
Because of its powerful anticoagulant features and selec-
tive action, APC is interesting to evaluate for therapeutic
intervention and APC has been shown to have antithrom-
botic features in different animal thrombosis models.
Thus, human APC (hAPC) is highly effective in non-
human primates [11-15]. Bovine APC (bAPC) is also
highly antithrombotic in arterial thrombosis models in
rabbits and rats, but only when co-administered with
bovine protein S (bPS), demonstrating the importance of
PS as a cofactor to bAPC and the species specificity in the
APC-PS interaction [16-19]. The results using hAPC in rat
models are more divergent. Earlier work showed anti-
thrombotic effects of even low doses of hAPC in different
models of thrombosis in the rat [20-24]. However, we
have been unable to demonstrate any antithrombotic
effects of hAPC in an arterial thrombosis model in
rats[25]. This model is dependent on both primary
hemostasis and on activation of blood coagulation, as
indicated by the antithrombotic effects of active-site
inhibited FVIIa, heparin and the combination of bovine
APC and bovine protein S[19,26,27].
Recently, we have created recombinant human APC
(hAPC) variants that have enhanced anticoagulant effects.
Selective mutagenesis of the phospholipid-binding Gla
domain generated the mutant QGNSEDY-hAPC, which
has increased affinity for negatively charged phospholip-
ids membranes and enhanced anticoagulant activ-
ity[28,29]. The protease domain has also been subjected
to mutagenesis aiming at improving the anticoagulant
activity of APC. By replacing the so-called 148 loop in
hAPC with the shorter bovine loop (the variant denoted
hAPC: B148), the catalytic and anticoagulant activity was
found to be enhanced [30]. By combining the mutations
above, a new mutant QGNSEDY-hAPC: B148 was con-
structed that due to the combination of increased binding
of the Gla-domain to phospholipid membranes and with
increased catalytic and anticoagulant effect was highly
anticoagulant [25]. Clotting experiments in rat plasma
showed distinct dose dependent anticoagulant effect,
especially with the mutant QGNSEDY-hAPC: B148 while
WT hAPC showed almost no anticoagulant effect. The
antithrombotic effect of the different variants of hAPC
was then tested in a rat model of deep arterial injury.
None of the APC variants had significant antithrombotic
effects [25]. However, human PS was not combined with
the APC in the experiments, which could explain the poor
effects. This hypothesis gained support from additional
evaluation of the anticoagulant effect of the hAPC variants
in vitro using rat plasma, which demonstrated hPS to
potentiate the anticoagulant activity of the two hAPC var-
iants. This observation formed the basis for the present
study, in which we explore the antithrombotic and antico-
agulant effects of co-administration of hAPC and hPS
using our arterial thrombosis model in the rat.
Materials and methods
Plasma Purified Proteins
Human APC was obtained from Chromogenix (Mölndal,
Sweden). Human protein S was purified as earlier
described [31]. Bovine protein C was purified as described
[32]. It was activated as previously described in detail
[16]. Bovine protein S was purified as described [33], with
modifications as in [31].
Recombinant Proteins
The QGNSEDY-hAPC carrying the Gla-domain mutations
H10Q/S11G/S12N/D23S/Q32E/N33D/H44Y was pre-
pared as described [28]. The hAPC: B148 mutant was con-
structed as described earlier [30]. In brief, the 148 loop in
hAPC, GWGYHSSREKEAKRN (the underlined amino
acids correspond to positions 303–310), was changed to
the four residues shorter corresponding loop in bAPC
(GWGYRDETKRN). The QGNSEDY- hAPC: B148 mutant
was prepared as described [25]. Recombinant hPS was
produced as previously described [34].
In vitro anticoagulant analyses
The in vitro anticoagulant effects of bAPC, hAPC, and the
recombinant hAPC variants with or without protein S (as
indicated in the figures) were investigated in rat plasma
and in human plasma. Rat plasma was acquired from
male Sprague-Dawley albino rats, and the plasma was
handled in the same way as in the in vivo experiments (see
below). Human citrated plasma was acquired from a mix-
ture of plasma from 30–40 volunteers without known
coagulation defects. In the APTT system, 50 μl of plasma
with or without added bPS or hPS 10 μg/ml (concentra-
tion in plasma) were mixed with 50 μl Platelin LS
(Biomerieux, Marcy l'Etoile, France) and incubated for
180 seconds at a temperature of 37°C before initiation of
coagulation by adding 50 μl of CaCl2 30 mM with differ-
ent concentrations of the APC variants (0, 5, 10, 20, 40,
80, 160 and 320 nM). The experiment was performed
three times in duplicate and the mean values of each pair
of analyses are presented. In the prothrombin time (PT),
50 μl plasma, with or without added bPS or hPS 10 μg/ml
was incubated for 180 seconds at a temperature of 37°C
before activation of coagulation by addition of 100 μl tis-
sues factor reagent (Simplastin Excel from Biomerieux),
diluted 1:50 in 1 × TBS+0.1% BSA+10 mM Ca2+ (1 × TBS
= 50 mM Tris-HCl, 0.15 M NaCl, pH 7.5), containing
increasing concentrations of APC variants (0, 5, 10, 20,
40, 80, 160 and 320 nM). The experiment was performed
twice and the assays were made in duplicate in one of the
experiments and once in the other. The mean values of theThrombosis Journal 2008, 6:16 http://www.thrombosisjournal.com/content/6/1/16
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double test and the single values of the other experiment
are presented. The clotting times were measured up to 200
seconds using an Amelung KC 10 instrument (Amelung
Heinrich, Lemgo, Germany).
APC inhibition in plasma
The chromogenic substrate S-2366 (kindly provided by
Chromogenix, Milano, Italy) was used to study the kinet-
ics of inhibition of the APC-variants in rat plasma at room
temperature. The concentration of added APC to rat
plasma was 50 nM and at different time points, the
remaining APC activity was measured with S-2366 hydrol-
ysis at 405 nm in an Automated Microplate Reader
(model EL 808, Bio-Tek Instruments, Winooski, VT,
U.S.A.).
Arterial thrombosis model
Sixty Sprague-Dawley male albino rats with a mean body
weight of 263 grams (range 226–312 grams) were used.
The Research Ethics Committee at Lund University
approved the experiments. The experimental model of
deep arterial injury was performed exactly as previously
described [19,25]. In summary, the right femoral vein was
cannulated for infusion of randomized substances and
blood sampling. After clamping the left common carotid
artery, a longitudinal incision exposed the inner vessel
layer. A five millimeter endarterectomy was performed by
microsurgical technique and deep vessel layers were
exposed. The arteriotomy was closed with micro sutures.
The clamps were removed and the vessel was reperfused.
All blood emerging from the suture line was collected by
preweighed cylindrical swabs to calculate the total blood
loss from the arteriotomy. Vessel patency was evaluated
31 minutes after reperfusion with the standard microvas-
cular empty-refill test and the vessel was classed as open
or occluded. One surgeon (K.M.) performed all opera-
tions. The mean total time for the experiments was 92
minutes (range 84–103).
Experimental Protocol
In a blind randomized study, 60 rats were divided into 5
groups that were treated either with recombinant hPS 0.6
mg/kg (n = 10), WT hAPC 0.8 mg/kg + hPS 0.6 mg/kg (n
= 10), QGNSEDY-hAPC 0.8 mg/kg + hPS 0.6 mg/kg (n =
10), QGNSEDY-hAPC: B148 0.8 mg/kg + hPS 0.6 mg/kg
(n = 10) or vehicle only (n = 20). The randomized sub-
stances were stored in 1.5 ml coded Eppendorf plastic
tubes (Sarstedt, Numbrecht, Germany) at -78°C and
thawed to room temperature immediately before use. The
substances were delivered as intravenous weight-adjusted
bolus injections after completing the vascular injury, one
minute before reperfusion. The infusion volume was 0.21
ml per 100-gram animal weight in all groups. The vehicle
was 20 mM Tris-HCl, 0.15 M NaCl, pH 7.5, containing
0.2% BSA.
Ex vivo coagulation analyses
Blood samples (0.9 ml) were drawn from the femoral vein
of the rats 1 minute before injection of the substance, then
2 and 30 minutes after reperfusion. Before each sample
was collected, 0.5 ml of blood was drawn into a separate
syringe and wasted. After every 0.9-ml sample was col-
lected, 0.5 ml of saline was injected with another syringe
to clear the catheter from blood. The samples were col-
lected with a 2-ml plastic syringe (Plastipak; Becton Dick-
inson AB, Hägersten, Stockholm, Sweden) prefilled with
0.1 ml of 3.8% 0.13 M sodium citrate. The samples were
immediately transferred to 1.5-ml Eppendorf plastic tubes
and centrifuged at 14 000 rpm for 3 minutes (Mikro 12/
24; Hettich Zentrifugen, Tuttlingen, Germany). The
plasma was separated with a pipette and put in two
Eppendorf tubes with 300 μl of plasma in each. The tubes
were put in a box containing pellets of carbon acid ice.
After completion of the daily experiments, the plasma
samples were transferred to a freezer maintaining a tem-
perature of -78°C. The APTT and PT assays were done as
described above with the exception that the Platelin LS
was diluted 1:2 in TBS+ 0.1% BSA.
Statistical Methods
Patency rates were compared using Fisher's exact test and
bleeding weights with the Mann-Whitney test. Statistics
were calculated using StatXact 4.0.1 software (Cytel Soft-
ware Corp., Cambridge, Mass., U.S.A.). Two-sided p-val-
ues are presented and p-values <0.05 were considered
statistically significant. No correction was made for multi-
ple testing.
Results
Anticoagulant effects of human APC variants in rat plasma
Plasma-derived human APC, even when combined with
human PS, yielded only a very small anticoagulant effect
in rat plasma (Fig. 1). Similar results were obtained with
recombinant WT APC and PS (Fig. 2). In contrast, in the
presence of hPS, both QGNSEDY-hAPC and QGNSEDY-
hAPC:B148 plus hPS approximately doubled the clotting
time in the whole dose range tested (Fig 2).
Rate of inhibition of APC variants in rat plasma
The APC variants were mixed with rat plasma and the rate
of inhibition of enzymatic activity measured (Fig. 3). The
recombinant hAPC variants showed similar t1/2, around
20 minutes. Bovine APC, used as control, is inhibited at a
slower rate with t1/2of 35 minutes.
Antithrombotic effect of hAPC variants?
In the groups with WT hAPC+hPS or QGNSEDY-
hAPC+hPS there was only one vessel open in each group.
In the group with QGNSEDY-hAPC:B148+hPS, there was
a trend towards antithrombotic effect as the patency rate
was 4/10 (Fig 4A), but the difference to the control groupThrombosis Journal 2008, 6:16 http://www.thrombosisjournal.com/content/6/1/16
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In Vitro anticoagulant response in rat plasma produced by plasma purified proteins Figure 1
In Vitro anticoagulant response in rat plasma produced by plasma purified proteins. Increasing concentrations of 
bAPC or hAPC, with or without PS (10 μg/ml), in rat (A+C) or human plasma (B+D) measured with either the APTT reagent 
Platelin LS (A+B) or with the tissue-factor reagent Simplastin Excel (C+D). Mean values and standard deviation (error bars) are 
presented. The indicated concentrations of APC refer to the concentrations of the proteins in the APC-containing solutions 
that were used to initiate the clotting reactions, as detailed in the Methods section. The experiments with bAPC in rat plasma, 
with or without bPS, were presented in one of our previous studies [19] and the same results are presented here again in the 
same figure as the experiments with hAPC, with or without hPS, in both plasma types to make comparisons possible.
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was not statistically significant (p = 0.14). The administra-
tion of hPS alone did not give any antithrombotic effect,
the patency rate (2/10 vessels) being similar to that of the
control group (2/20).
Arteriotomy bleeding
Administration of the different hAPC variants did not
increase the arteriotomy bleeding compared to controls
(Fig 4B). The cumulative arteriotomy bleeding during 31
minutes of observation was 1.1 grams (median) in the
control group and 0.68 to 1.3 grams (medians) in the
treatment groups. There was no statistically significant dif-
ference between the groups.
Ex vivo coagulation analyses
Administration of WT hAPC+hPS or hPS alone only
slightly increased the clotting time (Fig 5A and 5B). Three
minutes after injection of QGNSEDY-hAPC+hPS, the
APTT and PT times increased 1.6 and 1.3 times, respec-
tively. Corresponding values for QGNSEDY-
hAPC:B148+hPS were 1.9 and 1.5 times. At 31 minutes
after injection, the clotting times had almost returned to
baseline levels in all groups (Fig. 5A and 5B).
Discussion
In our arterial thrombosis model in the rat, we find no
antithrombotic effect of WT hAPC [25] even when we
now give WT hAPC together with hPS. This is in contrast
to results obtained in other thrombosis models in the rat,
where hAPC has been reported to have antithrombotic
properties [20-24]. The discrepancy may be due to differ-
ences in the type of vascular trauma. Our model includes
a crude vascular trauma producing occlusive thrombi, and
is quite resistant to antithrombotic intervention. It was
developed to mimic conditions encountered in clinical
vascular surgery. However, despite being arterial and
In vitro anticoagulant response in rat plasma to added APC variants Figure 2
In vitro anticoagulant response in rat plasma to added APC variants. Different concentrations of WT hAPC, or the 
two mutants of hAPC, with or without recombinant hPS (10 μg/ml) were added in coagulation tests using either the APTT rea-
gent Platelin LS (A) or the tissue-factor reagent Simplastin Excel (B). Note that the APTT reagent was diluted 1/2 to make the 
assay more sensitive. Therefore, it can be concluded that the hAPC variants + hPS have lower anticoagulant potential than the 
bAPC+bPS combination shown in figure 1, even though the prolongation of clotting times are similar. Each experiment was 
performed three times with measurements in duplicate. Mean values are presented. The indicated concentrations of hAPC 
represent the final concentrations. The experiments without hPS were performed and presented in our previous study [25] 
and the same results are presented here again in conjunction with the tests with hPS, to make comparisons possible.
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involving primary hemostasis events, the model is also
dependent on activation of blood coagulation and sensi-
tive to anticoagulant substances[19,26,27].
The interaction between APC and PS is species-specific,
which makes cross-species studies more difficult. How-
ever, it can also be an advantage and help clarify the
importance of the cofactor function of PS. Thus, we have
found bAPC to be a highly efficient antithrombotic agent
in arterial thrombosis models with patency rates reaching
90–100% in both rat and rabbit, but only when bovine PS
was given together with the bAPC [17-19]. This agrees
with results of clotting assays, in which bAPC is highly
anticoagulant in human, rabbit, and rat plasmas in the
presence of bovine PS, but not in its absence [35,36].
Human APC has shown anticoagulant effects in bovine,
baboon and rabbit plasmas, suggesting that hAPC is able
to interact with PS from different origin [33-37]. However,
Inactivation of APC in rat plasma Figure 3
Inactivation of APC in rat plasma. The different APC variants were added to rat plasma and at various time points; the 
remaining amidolytic activity was measured at 405 nm using the synthetic substrate S-2366. The absorbance reading of plain rat 
plasma was subtracted from the mean of two absorbance readings at each time point and the difference was used for presenta-
tion. The three recombinant hAPC variants were tested in one experiment and bAPC was tested in another experiment and 
the results were combined into one figure.
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we now find almost no hAPC cofactor effect of hPS in rat
plasma.
As hAPC was inactive in our thrombosis model, we were
interested in evaluating the antithrombotic effects of two
hAPC variants (QGNSEDY-hAPC and QGNSEDY-hAPC:
B148) having enhanced anticoagulant activity. These
mutants, despite giving an anticoagulant response in rat
plasma, did not give a significant antithrombotic effect
when given alone in our arterial thrombosis model, i.e. no
co-administration of hPS [25]. We have now investigated
the possible beneficial effects of co-infusion of the hAPC
variants with hPS. The results show that neither form of
hAPC produced significant antithrombotic effects and
although QGNSEDY-hAPC: B148 increased the vessel pat-
ency rate compared to the controls, the difference did not
reach significance.
The discrepant findings in the thrombosis model between
human and bovine APC are interesting. In coagulation
tests performed both in vitro and ex vivo, bAPC plus bPS
yielded stronger anticoagulant response [19] than the
combination of hAPC variants plus hPS (Fig 2 and 5),
which should contribute to the lower anti-thrombotic
effects of the hAPC variants. Another factor is the differ-
ence in elimination kinetics between the bovine and
human APC, the half-life of bAPC in rat plasma being
almost twice as long as those of the hAPC variants (Fig. 3).
APC is inhibited in plasma mainly by two serpins, α1-anti-
trypsin (α1-AT) and protein C inhibitor (PCI) [38,39].
Effects of WT hAPC and the two mutants of hAPC combined with hPS in the rat model of arterial thrombosis Figure 4
Effects of WT hAPC and the two mutants of hAPC combined with hPS in the rat model of arterial thrombosis. 
Experimental group numbers in A and B refer to the following proteins: 1 = hPS, 2 = WT-hAPC + hPS, 3 = QGNSEDY-hAPC 
+ hPS, 4 = QGNSEDY-hAPC:B148 + hPS, 5 = Vehicle. A. Antithrombotic effect, expressed as the percentage of patent vessels. 
None of the hAPC variants combined with hPS produced any significant antithrombotic effect, although QNSEDY-
hAPC:B148+hPS resulted in an increased patency-rate compared to controls with p = 0.14 (n = 10 in all treatment groups, n = 
20 in the control group). B. Arteriotomy bleeding (n = 10 in all treatment groups, n = 20 in the control group). All observa-
tions are plotted as well as the 25th, 50th (medians) and 75th percentiles (within boxes). There were no statistical significant dif-
ferences between the groups.
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Bovine APC has been shown to be resistant to inhibition
by α1-AT in vitro and the structural requirements for this
has been investigated [40]. The low anticoagulant effect of
hAPC in rat plasma may also suggest that rat FVa and FVI-
IIa are poor substrates for hAPC. In this context it is inter-
esting that more than ten-fold higher concentration of
hAPC was needed to inactivate rat FVa as compared to
human FVa [41].
Conclusion
In conclusion, in an arterial thrombosis model in the rat
we find no significant antithrombotic effects of neither
WT-hAPC nor hAPC variants with enhanced anticoagu-
lant activity even when the human APC cofactor PS was
co-injected. Our results underline the difficulties in using
reagents across the species borders and calls for the crea-
tion of corresponding APC variants with the same species
background as the animals that are used in the thrombo-
sis model.
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